Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYXIN versus DIFICID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYXIN versus DIFICID.
CHLOROMYXIN vs DIFICID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloromyxin is a combination product of chloramphenicol and polymyxin B. Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides in gram-negative bacteria.
Fidaxomicin is a macrocyclic antibiotic that inhibits bacterial RNA polymerase, leading to RNA synthesis inhibition and cell death. It is bactericidal against Clostridioides difficile and has minimal systemic absorption.
500 mg IV every 6 hours or 1 g IV every 12 hours; infusion over 30 minutes.
200 mg (tablet) orally twice daily for 10 days.
None Documented
None Documented
CHLOROMYXIN is not a recognized drug. No data available.
11.7 hours (terminal half-life in healthy subjects); supports twice-daily dosing.
CHLOROMYXIN is not a recognized drug. No data available.
Fecal (primarily as unchanged drug, ~44% of dose); renal (~1.6% unchanged, <1% as metabolites); biliary (minor).
Category C
Category C
Antibiotic
Antibiotic